← Leaderboards
Jonathan W. Weinsaft
Weill Medical Coll Of Cornell Univ
$12,053,026
Attributed
$21,692,113
Total exposure
8
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2010–25$10M$7.5M$5M$2.5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,692,113 · 8
By mechanism
R01$12,917,148 · 4
R33$5,884,638 · 1
T32$1,789,549 · 1
K23$680,400 · 1
R61$420,378 · 1
Top collaborators
- Mario Fl Gaudino6 shared
- Pascal Spincemaille6 shared
- Ronald G Crystal4 shared
- Stephen Michael Kaminsky4 shared
- Geoffrey S Pitt4 shared
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Jiwon Kim$4,201,792
- Lisa Qia Rong$953,845
- Pascal Spincemaille$5,415,841
- Stephen Michael Kaminsky$4,824,238
- Mario Fl Gaudino$5,803,713
Others in their field
Top investigators on “Cessation Of Life”
- David R. Weir · University Of Michigan At Ann Arbor$345,522,974
- John M Lachin · George Washington University$134,302,892
- David M Nathan · Massachusetts Institute Of Technology$127,791,564
- Judith S Hochman · New York University School Of Medicine$112,898,313
- Jeffrey H Samet · Boston University Medical Campus$91,739,367
- Judith S. Currier · University Of California Los Angeles$85,330,415
Research focus
Cessation Of LifeCardiacLeftInsightMagnetic Resonance ImagingHeart FailureLinkTissuesVentricularTechnologyReportingStemPropertySeveritiesDecision MakingIndexingBreathingClinical ResearchFollow-UpEchocardiographyPerfusionMortalityBloodLeft Ventricular Remodeling
Grant awards (30)
Noninvasive measurement of oxygenation using quantitative susceptibility mapping$770,820
R01 · FY2025 · HL
Cardiac Magnetic Resonance Tissue Characterization of Ischemic and Non-Ischemic Myocardium to Predict Left Ventricular Functional Recovery and Outcomes after Multivessel Coronary Revascularization$741,527
R01 · FY2025 · HL
Towards Personalized Prosthetic Graft Replacement for Genetically Triggered Thoracic Aortic Aneurysms$699,190
R01 · FY2025 · HL · contact PI
Multidisciplinary Research Training in Cardiovascular Disease$602,713
T32 · FY2025 · HL
Phase IA/IB Study of AAVrh.10hFXN Therapy to Treat the Cardiomyopathy of Friedreich's Ataxia$1,380,330
R33 · FY2024 · HL
Noninvasive measurement of oxygenation using quantitative susceptibility mapping$782,671
R01 · FY2024 · HL
Cardiac Magnetic Resonance Tissue Characterization of Ischemic and Non-Ischemic Myocardium to Predict Left Ventricular Functional Recovery and Outcomes after Multivessel Coronary Revascularization$739,298
R01 · FY2024 · HL
Towards Personalized Prosthetic Graft Replacement for Genetically Triggered Thoracic Aortic Aneurysms$691,821
R01 · FY2024 · HL · contact PI
Multidisciplinary Research Training in Cardiovascular Disease$599,210
T32 · FY2024 · HL
Phase IA/IB Study of AAVrh.10hFXN Therapy to Treat the Cardiomyopathy of Friedreich's Ataxia$2,104,654
R33 · FY2023 · HL
Noninvasive measurement of oxygenation using quantitative susceptibility mapping$816,383
R01 · FY2023 · HL
Cardiac Magnetic Resonance Tissue Characterization of Ischemic and Non-Ischemic Myocardium to Predict Left Ventricular Functional Recovery and Outcomes after Multivessel Coronary Revascularization$780,793
R01 · FY2023 · HL
Towards Personalized Prosthetic Graft Replacement for Genetically Triggered Thoracic Aortic Aneurysms$750,241
R01 · FY2023 · HL · contact PI
Noninvasive measurement of oxygenation using quantitative susceptibility mapping (supplement)$700,348
R01 · FY2023 · HL
Multidisciplinary Research Training in Cardiovascular Disease$395,450
T32 · FY2023 · HL
Phase IA/IB Study of AAVrh.10hFXN Therapy to Treat the Cardiomyopathy of Friedreich's Ataxia$2,399,654
R33 · FY2022 · HL
Noninvasive measurement of oxygenation using quantitative susceptibility mapping$830,748
R01 · FY2022 · HL
Multidisciplinary Research Training in Cardiovascular Disease$192,176
T32 · FY2022 · HL
Noninvasive measurement of oxygenation using quantitative susceptibility mapping$778,098
R01 · FY2021 · HL
Phase IA/IB Study of AAVrh.10hFXN Therapy to Treat the Cardiomyopathy of Friedreich's Ataxia$420,378
R61 · FY2020 · HL
CMR Myocardial Tissue Based Prediction of Ischemic MR Revascularization Response$700,309
R01 · FY2019 · HL · contact PI
CMR Myocardial Tissue Based Prediction of Ischemic MR Revascularization Response$764,655
R01 · FY2018 · HL · contact PI
CMR Myocardial Tissue Based Prediction of Ischemic MR Revascularization Response$764,655
R01 · FY2017 · HL · contact PI
CMR Myocardial Tissue Based Prediction of Ischemic MR Revascularization Response$765,007
R01 · FY2016 · HL · contact PI
CMR Myocardial Tissue Based Prediction of Ischemic MR Revascularization Response$840,584
R01 · FY2015 · HL · contact PI
Delayed Enhancement MRI for Detection of Sub-Clinical Papillary Muscle Infarction$136,080
K23 · FY2014 · HL · contact PI
Delayed Enhancement MRI for Detection of Sub-Clinical Papillary Muscle Infarction$136,080
K23 · FY2013 · HL · contact PI
Delayed Enhancement MRI for Detection of Sub-Clinical Papillary Muscle Infarction$136,080
K23 · FY2012 · HL · contact PI
Delayed Enhancement MRI for Detection of Sub-Clinical Papillary Muscle Infarction$136,080
K23 · FY2011 · HL · contact PI
Delayed Enhancement MRI for Detection of Sub-Clinical Papillary Muscle Infarction$136,080
K23 · FY2010 · HL · contact PI